bromocriptine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
ergot alkaloid derivatives 403 25614-03-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • bromocriptine
  • bromocriptin
  • bromocryptine
  • ergolactin
  • 2-bromoergocriptine
  • bromocriptine mesylate
  • bromocriptine mesilate
A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.
  • Molecular weight: 654.61
  • Formula: C32H40BrN5O5
  • CLOGP: 6.58
  • LIPINSKI: 2
  • HAC: 10
  • HDO: 3
  • TPSA: 118.21
  • ALOGS: -3.88
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mg O
5 mg P
40 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.80 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.19 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 28 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
June 28, 1978 FDA US PHARMS HOLDINGS I

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Exposure during pregnancy 62.60 19.84 56 3125 155491 63330350
Blood prolactin increased 60.97 19.84 17 3164 3486 63482355
Visual pathway disorder 58.76 19.84 8 3173 30 63485811
Neuroleptic malignant syndrome 57.77 19.84 22 3159 12034 63473807
Mediastinal fibrosis 43.96 19.84 6 3175 23 63485818
Pituitary tumour 38.26 19.84 9 3172 939 63484902
Pituitary tumour removal 37.84 19.84 5 3176 14 63485827
Hypersexuality 32.16 19.84 7 3174 515 63485326
Body height increased 31.18 19.84 5 3176 67 63485774
Maternal exposure during pregnancy 30.93 19.84 46 3135 220016 63265825
Psychomotor hyperactivity 29.05 19.84 13 3168 10650 63475191
Insulin-like growth factor increased 28.22 19.84 7 3174 912 63484929
Pituitary tumour benign 27.17 19.84 8 3173 1987 63483854
Muscle neoplasm 26.30 19.84 4 3177 37 63485804
Gallbladder neoplasm 26.11 19.84 4 3177 39 63485802
Lymphatic system neoplasm 25.76 19.84 4 3177 43 63485798
Blood creatine phosphokinase increased 25.56 19.84 17 3164 30413 63455428
Arteriospasm coronary 25.53 19.84 9 3172 3959 63481882
Hemianopia heteronymous 25.51 19.84 4 3177 46 63485795
Blood prolactin decreased 25.13 19.84 4 3177 51 63485790
Catatonia 24.46 19.84 9 3172 4468 63481373
Compulsive shopping 24.41 19.84 6 3175 753 63485088
Pituitary haemorrhage 22.99 19.84 4 3177 90 63485751
Gastrointestinal hypomotility 22.31 19.84 6 3175 1075 63484766
Normal newborn 22.18 19.84 10 3171 8331 63477510
Eating disorder 21.95 19.84 13 3168 19003 63466838
Genital swelling 21.51 19.84 4 3177 132 63485709
Gambling disorder 21.43 19.84 6 3175 1246 63484595
Hormone level abnormal 21.34 19.84 7 3174 2476 63483365
Volume blood decreased 21.25 19.84 4 3177 141 63485700
Peripartum cardiomyopathy 20.99 19.84 4 3177 151 63485690
Alveolar lung disease 20.96 19.84 4 3177 152 63485689
Psychotic behaviour 20.60 19.84 5 3176 595 63485246

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Gambling disorder 85.60 26.35 19 1624 1641 34953647
Neuroleptic malignant syndrome 85.51 26.35 32 1611 17902 34937386
Serotonin syndrome 68.29 26.35 28 1615 19905 34935383
Muscle rigidity 65.97 26.35 23 1620 10495 34944793
Stress cardiomyopathy 60.82 26.35 15 1628 2044 34953244
Impulse-control disorder 46.21 26.35 11 1632 1290 34953998
Neonatal respiratory depression 39.98 26.35 8 1635 417 34954871
Hypersexuality 39.69 26.35 10 1633 1483 34953805
Borderline personality disorder 34.65 26.35 7 1636 383 34954905
Premature baby 33.53 26.35 17 1626 19616 34935672
Blood creatine phosphokinase increased 29.49 26.35 21 1622 44836 34910452

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 117.06 19.43 47 4254 27512 79712575
Muscle rigidity 81.27 19.43 33 4268 19849 79720238
Blood prolactin increased 70.80 19.43 20 4281 3991 79736096
Visual pathway disorder 59.15 19.43 9 4292 77 79740010
Exposure during pregnancy 53.49 19.43 44 4257 101088 79638999
Blood creatine phosphokinase increased 50.94 19.43 36 4265 66054 79674033
Stress cardiomyopathy 47.22 19.43 19 4282 11147 79728940
Gambling disorder 44.51 19.43 12 4289 2014 79738073
Mediastinal fibrosis 44.17 19.43 6 4295 20 79740067
Serotonin syndrome 42.96 19.43 28 4273 44999 79695088
Maternal exposure during pregnancy 40.39 19.43 43 4258 136495 79603592
Pituitary tumour benign 37.24 19.43 11 4290 2565 79737522
Pituitary tumour removal 35.71 19.43 5 4296 22 79740065
Abnormal behaviour 33.16 19.43 22 4279 36399 79703688
Psychomotor hyperactivity 30.83 19.43 16 4285 16833 79723254
Pituitary tumour 30.47 19.43 8 4293 1214 79738873
Aortic valve incompetence 29.53 19.43 13 4288 9517 79730570
Pituitary haemorrhage 29.30 19.43 6 4295 305 79739782
Impulse-control disorder 27.51 19.43 8 4293 1766 79738321
Mitral valve incompetence 25.39 19.43 17 4284 28548 79711539
Delusion 25.30 19.43 15 4286 20408 79719679
Muscle neoplasm 24.55 19.43 4 4297 55 79740032
Lymphatic system neoplasm 24.16 19.43 4 4297 61 79740026
Hypersexuality 23.53 19.43 7 4294 1673 79738414
Normal newborn 23.06 19.43 10 4291 7062 79733025
Gallbladder neoplasm 22.82 19.43 4 4297 87 79740000
Insulin-like growth factor increased 22.73 19.43 7 4294 1879 79738208
Hemianopia heteronymous 22.52 19.43 4 4297 94 79739993
Adenoma benign 21.46 19.43 6 4295 1152 79738935
Catatonia 21.01 19.43 10 4291 8746 79731341
Body height increased 20.96 19.43 4 4297 141 79739946
Peripartum cardiomyopathy 20.85 19.43 4 4297 145 79739942
Tricuspid valve incompetence 20.63 19.43 13 4288 19699 79720388
Abortion 20.29 19.43 6 4295 1404 79738683
Arteriospasm coronary 20.29 19.43 9 4292 6707 79733380
Stupor 20.09 19.43 9 4292 6863 79733224
Cardiomegaly 19.47 19.43 14 4287 26338 79713749

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G02CB01 GENITO URINARY SYSTEM AND SEX HORMONES
OTHER GYNECOLOGICALS
OTHER GYNECOLOGICALS
Prolactine inhibitors
ATC N04BC01 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
DOPAMINERGIC AGENTS
Dopamine agonists
FDA CS M0007652 Ergolines
CHEBI has role CHEBI:48407 antiparkinson agent
CHEBI has role CHEBI:49020 hormone antagonists
CHEBI has role CHEBI:51065 Dopamine receptor agonist
CHEBI has role CHEBI:66956 antidyskinetic agent
MeSH PA D018726 Anti-Dyskinesia Agents
MeSH PA D000978 Antiparkinson Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D015259 Dopamine Agents
MeSH PA D018491 Dopamine Agonists
MeSH PA D006727 Hormone Antagonists
MeSH PA D018377 Neurotransmitter Agents
FDA EPC N0000175827 Ergot Derivative

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Postencephalitic parkinsonism indication 19972008 DOID:14332
Parkinson's disease indication 49049000 DOID:14330
Acromegaly indication 74107003 DOID:2449
Hyperprolactinemia indication 237662005 DOID:12700
Type 2 Diabetes Mellitus Treatment Adjunct indication
Neuroleptic malignant syndrome off-label use 15244003 DOID:14464
Hypertensive disorder contraindication 38341003 DOID:10763
Mild pre-eclampsia contraindication 41114007
Severe pre-eclampsia contraindication 46764007
Pregnancy-induced hypertension contraindication 48194001
Eclampsia in pregnancy contraindication 198992004
Cerebrovascular accident contraindication 230690007
Disease of liver contraindication 235856003 DOID:409
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Hypertensive urgency contraindication 443482000
Psychiatric Disturbance contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.98 acidic
pKa2 12.93 acidic
pKa3 5.98 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 7888310 July 25, 2023 IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 8137992 July 25, 2023 IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 8137993 July 25, 2023 IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 8137994 July 25, 2023 IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 10
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 11
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 13
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 9
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 22 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 26 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 44 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 44 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 44 AND 54
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1, 17 AND 18 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 15 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 16 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 17 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 2 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 3 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 4 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 5 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 6 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 8 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 23 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 24 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 25 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 27 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 28 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 29 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 30 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 31 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 32 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 33 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 34 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 36 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 38 AND WHEREIN THE EFFECTS ARE AS RECITED CLAIM 26
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 39 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 40 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 45 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 46 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 47 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 48 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 49 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 50 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 51 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 52 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 56 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 57 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 42 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 42
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 42 AND 43 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 42
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688155 June 7, 2030 ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 8877708 June 7, 2030 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE WHEREIN THE COMBINED THERAPEUTIC EFFECT IS GREATER THAN THE ADDITIVE EFFECT OF ADMINISTERING EACH AGENT ALONE
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9352025 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 10 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 10
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9352025 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 12 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 12
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9352025 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 19
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9352025 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 6 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 6
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9352025 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 7
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9352025 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 9 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 9
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9352025 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1-5 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1-5
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9352025 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 14-15 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 14-15
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9352025 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-18 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-18
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9895422 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 11 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 11
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9895422 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 12 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 12
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9895422 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 14 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 14
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9895422 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9895422 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 8 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 8
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9895422 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 9 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 9
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9895422 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-19
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9895422 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 3-7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 3-7
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9895422 June 7, 2030 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 2 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 2
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688094 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 2
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688094 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 2 AND 3
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688094 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 4, 5, AND 6
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688094 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 4 AND 5
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688094 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 10, 11, AND 12
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688094 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 10 AND 11
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688094 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13, 14, AND 15
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688094 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13 AND 14
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688094 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 16, 17, AND 18
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688094 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 16 AND 17
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688094 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 19, 20, AND 21
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688094 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 19 AND 20
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688094 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 22, 23, AND 24
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688094 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 25, 26, AND 27
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688094 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 25 AND 26
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688094 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 28, 29, AND 30
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688094 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 28 AND 29
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688094 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 7, 8, AND 9
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 10688094 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 7 AND 8
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 11000522 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 11, AND 12
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 11000522 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13 AND 23
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 11000522 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 11
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 11000522 April 30, 2032 ADJUNCT TO DIET EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13, 23, AND 24
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 8431155 April 30, 2032 IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 8613947 April 30, 2032 IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9192576 April 30, 2032 IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9522117 April 30, 2032 ADMINISTRATION ONCE DAILY WITHIN TWO HOURS AFTER WAKING IN THE MORNING FOR IMPROVEMENT OF GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9522117 April 30, 2032 IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9700555 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15, 27, AND 28
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9700555 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15 AND 27
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9700555 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66, 75, AND 76
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9700555 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66 AND 75
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9700555 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 13, AND 14
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9700555 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 13
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9700555 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29, 39, AND 40
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9700555 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29 AND 39
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9700555 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41, 52, AND 53
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9700555 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41 AND 52
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9700555 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54, 64, AND 65
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9700555 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54 AND 64
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9700555 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77, 87, AND 88
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9700555 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77 AND 87
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9700555 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89, 99, AND 100
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9700555 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89 AND 99
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9993474 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12, 19 AND 20
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9993474 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12 AND 19
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9993474 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 21, 28, AND 29
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9993474 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 21 AND 28
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9993474 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 30, 41, AND 42
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9993474 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 30 AND 41
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9993474 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 43, 50 AND 51
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9993474 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 43 AND 50
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9993474 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1,10 AND 11
EQ 0.8MG BASE CYCLOSET VEROSCIENCE N020866 May 5, 2009 RX TABLET ORAL 9993474 April 30, 2032 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 10

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
D(2) dopamine receptor GPCR AGONIST Ki 9.70 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 6 GPCR AGONIST Ki 7.50 IUPHAR
Beta-1 adrenergic receptor GPCR Ki 5.86 DRUG MATRIX
Beta-2 adrenergic receptor GPCR Ki 6.13 PDSP
D(1A) dopamine receptor GPCR AGONIST Ki 6.20 IUPHAR
Alpha-2A adrenergic receptor GPCR Ki 8 WOMBAT-PK
Cytochrome P450 3A4 Enzyme IC50 5.70 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 7.90 WOMBAT-PK
5-hydroxytryptamine receptor 2A GPCR Ki 7 WOMBAT-PK
5-hydroxytryptamine receptor 2B GPCR Ki 7.30 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 8.38 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 7.50 WOMBAT-PK
D(3) dopamine receptor GPCR AGONIST Ki 7.50 WOMBAT-PK
D(1B) dopamine receptor GPCR AGONIST Ki 6.30 IUPHAR
5-hydroxytryptamine receptor 1B GPCR Ki 6.50 WOMBAT-PK
5-hydroxytryptamine receptor 1D GPCR Ki 8 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 7.60 WOMBAT-PK
D(4) dopamine receptor GPCR ANTAGONIST Ki 6.40 IUPHAR
Alpha-1D adrenergic receptor GPCR Ki 8.55 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 8.86 PDSP
Alpha-synuclein Transporter IC50 4.61 CHEMBL
5-hydroxytryptamine receptor 2C GPCR Ki 6.10 WOMBAT-PK
Androgen receptor Transcription factor Ki 5.82 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 8.71 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 7.33 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 8.16 CHEMBL
D(2) dopamine receptor GPCR Kd 8.40 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 8.25 CHEMBL
5-hydroxytryptamine receptor 7 GPCR AGONIST Ki 8 IUPHAR
Vesicular glutamate transporter 3 Transporter IC50 4.66 CHEMBL
5-hydroxytryptamine receptor 6 GPCR AGONIST Ki 7.50 IUPHAR
Adrenergic receptor alpha-2 GPCR IC50 6.29 CHEMBL
Dopamine receptor GPCR IC50 7.55 CHEMBL
Cerebral cortex alpha adrenergic receptor GPCR IC50 6.29 CHEMBL
Genome polyprotein Unclassified EC50 4.89 CHEMBL

External reference:

IDSource
4019639 VUID
N0000147732 NUI
D00780 KEGG_DRUG
22260-51-1 SECONDARY_CAS_RN
142426 RXNORM
C0006230 UMLSCUI
CHEBI:3181 CHEBI
08Y PDB_CHEM_ID
CHEMBL493 ChEMBL_ID
CHEMBL311816 ChEMBL_ID
CHEMBL1200503 ChEMBL_ID
D001971 MESH_DESCRIPTOR_UI
DB01200 DRUGBANK_ID
35 IUPHAR_LIGAND_ID
3365 INN_ID
3A64E3G5ZO UNII
31101 PUBCHEM_CID
10007 MMSL
4300 MMSL
d00178 MMSL
116656002 SNOMEDCT_US
387039007 SNOMEDCT_US
46293006 SNOMEDCT_US
4018752 VANDF
4019639 VANDF
002117 NDDF
002118 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Bromocriptine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0378-7096 CAPSULE 5 mg ORAL ANDA 21 sections
Bromocriptine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0574-0106 TABLET 2.50 mg ORAL ANDA 22 sections
Bromocriptine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0781-5325 TABLET 2.50 mg ORAL ANDA 18 sections
Parlodel HUMAN PRESCRIPTION DRUG LABEL 1 30698-201 CAPSULE, GELATIN COATED 5 mg ORAL NDA 21 sections
Parlodel HUMAN PRESCRIPTION DRUG LABEL 1 30698-201 CAPSULE, GELATIN COATED 5 mg ORAL NDA 21 sections
Parlodel HUMAN PRESCRIPTION DRUG LABEL 1 30698-202 TABLET 2.50 mg ORAL NDA 21 sections
Parlodel HUMAN PRESCRIPTION DRUG LABEL 1 30698-202 TABLET 2.50 mg ORAL NDA 21 sections
Bromocriptine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 54868-5667 TABLET 2.50 mg ORAL ANDA 22 sections
Bromocriptine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60687-286 TABLET 2.50 mg ORAL ANDA 18 sections
Bromocriptine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60687-286 TABLET 2.50 mg ORAL ANDA 18 sections
Bromocriptine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60687-286 TABLET 2.50 mg ORAL ANDA 18 sections
BROMOCRIPTINE MESYLATE HUMAN PRESCRIPTION DRUG LABEL 1 63304-158 CAPSULE 5 mg ORAL NDA 14 sections
BROMOCRIPTINE MESYLATE HUMAN PRESCRIPTION DRUG LABEL 1 63304-962 TABLET 2.50 mg ORAL NDA 14 sections
Bromocriptine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 65841-654 CAPSULE 5 mg ORAL ANDA 1 sections
Bromocriptine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 65841-654 CAPSULE 5 mg ORAL ANDA 1 sections
CYCLOSET HUMAN PRESCRIPTION DRUG LABEL 1 68012-258 TABLET 0.80 mg ORAL NDA 30 sections
Bromocriptine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 68151-1305 TABLET 2.50 mg ORAL ANDA 23 sections
Bromocriptine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 68382-110 CAPSULE 5 mg ORAL ANDA 13 sections
Bromocriptine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 68382-110 CAPSULE 5 mg ORAL ANDA 13 sections